source
- AstraZeneca halts Phase 3 lung cancer trial of volrustomig after negative resultsAstraZeneca announced on Monday that it is ending the Phase 3 study of its lung-cancer drug volrustomig after the trial failed to meet its primary efficacy endpoints. The company said the data did…
- FDA releases first updated guidance in 27 years on container and closure systems for drugs and biologicsThe FDA announced a draft guidance that updates the agency’s recommendations for evaluating container and closure systems used in the packaging of new drugs and biologics. This revision is the fir…